Burjeel and Avatrial forge transformative partnership to establish AI-powered cancer research ecosystem in Abu Dhabi
A landmark collaboration between Burjeel Holdings and Cambridge-affiliated biotechnology innovator Avatrial promises to establish an integrated discovery platform that harnesses artificial intelligence and patient-derived insights to advance cancer therapeutics from laboratory to clinical application.
Burjeel Holdings and Avatrial, a distinguished biotechnology enterprise rooted in academic excellence at the University of Cambridge, have entered into a strategic partnership to establish an unprecedented AI-powered cancer drug discovery ecosystem within Abu Dhabi. The Memorandum of Understanding, ceremonially signed at the Abu Dhabi Future Health Summit, represents a transformative commitment to positioning the Emirate as a preeminent global centre for biotechnological innovation and precision medicine.
This collaborative venture unites Burjeel Holdings’ profound clinical acumen and sophisticated patient-centered research infrastructure with Avatrial’s cutting-edge artificial intelligence biotechnology platform. The integrated model represents a departure from conventional approaches, enabling researchers to translate insights derived from cancer patients into the identification and development of promising new therapeutic approaches, with the ultimate ambition of advancing candidates into rigorous clinical trials.
The proposed discovery-to-clinic framework orchestrates a seamless integration of clinical data, molecular analysis, and experimental investigation to elucidate the biological mechanisms underlying malignancy and discern potential treatment pathways. By leveraging Burjeel Holdings’ expansive clinical network and the distinguished oncological expertise housed within Burjeel Cancer Institute, complemented by Avatrial’s sophisticated multi-omics technologies and patient-derived experimental models, the partnership establishes a uniquely powerful investigative platform.
Within this rigorously governed framework, ethically consented surplus tumour tissue and appropriately de-identified clinical data shall undergo sophisticated analysis, subject to requisite regulatory and ethical authorisation. Artificial intelligence-assisted molecular profiling shall facilitate the identification of potential therapeutic targets, whilst patient-derived models will serve to evaluate and validate promising pharmaceutical candidates. Those demonstrating compelling potential through preclinical assessment may subsequently progress into clinical development, contingent upon further collaborative agreements and regulatory approval. Nurion CRO, affiliated with Burjeel, shall provide essential support throughout the clinical research and trial development trajectory.
This collaboration embodies Burjeel 2.0, the Group’s transformative strategy to advance complex care, clinical research, and artificial intelligence integration across its comprehensive healthcare ecosystem. It simultaneously reflects Burjeel’s broader aspiration to cultivate capabilities in therapeutic innovation whilst meaningfully contributing to Abu Dhabi’s visionary objective of establishing itself as a preeminent global hub for life sciences, precision medicine, and healthcare innovation.
Burjeel’s considerable foundation encompasses established expertise in complex oncology, precision medicine, and translational research. Through Burjeel Cancer Institute, the organisation has cultivated a sophisticated multidisciplinary oncology ecosystem, enriched by advanced diagnostic imaging, molecular profiling, and specialised treatments encompassing medical, surgical, and radiation oncology disciplines. Burjeel Medical City in Abu Dhabi operates as a flagship centre for complex cancer care, assembling multidisciplinary teams devoted to managing the most challenging clinical presentations. The Group’s research portfolio encompasses clinical trials, scientific collaborations, and programmes addressing rare blood disorders, precision medicine, and emerging cellular and gene therapies.
The partnership commences with a feasibility programme focused upon selected solid tumours, assessing the integration of clinical samples, molecular profiling, artificial intelligence-based analysis, and experimental validation within a coordinated research framework. The resulting findings shall inform decisions regarding potential joint therapeutic development programmes, opportunities to strengthen local research infrastructure, and the expansion of scientific capabilities throughout Abu Dhabi. Prospectively, this model possesses the potential to extend beyond oncology into additional therapeutic domains, encompassing rare and inherited diseases.
This collaboration additionally cultivates enriched scientific cooperation between the United Arab Emirates and the United Kingdom, synthesising regional clinical expertise with international biotechnology research capabilities to advance therapeutic innovation of genuine global significance.
Source: WAM